Immunic Inc
NASDAQ:IMUX

Watchlist Manager
Immunic Inc Logo
Immunic Inc
NASDAQ:IMUX
Watchlist
Price: 0.5666 USD -2.31%
Market Cap: 68.2m USD

Operating Margin
Immunic Inc

0%
Current
0%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-105.5m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DE
Immunic Inc
NASDAQ:IMUX
68.6m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
393.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
174.5B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
150.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
28%
AU
CSL Ltd
ASX:CSL
84.8B AUD
26%
NL
argenx SE
XBRU:ARGX
44.5B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.2B USD
8%
No Stocks Found

Immunic Inc
Glance View

Market Cap
68.6m USD
Industry
Biotechnology

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 55 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The firm is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.

IMUX Intrinsic Value
1.1456 USD
Undervaluation 51%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-105.5m
/
Revenue
0
What is the Operating Margin of Immunic Inc?

Based on Immunic Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top